抄録
SPG (a β-1, 3-D-glucan from Schizophyllum commune Fries) is known as one of the immunopotentiating agent showing antineoplastic effects in experimental animals. SPG was administered intramuscularly 40 milligrams a week for three months to 30 patients with head and neck malignant tumors in combination with the usual therapy of surgery, irradiation and chemotherapy. Therapeutic effect of SPG was evaluated from the clinical standpoint. Results were as follows: ten extremely effective, one effective, seven slightly effective, ten ineffective. Neutrophil function tests were performed at pre-and post-treatmentstages. Both chemotactic activity under agarose plate and NBT reductive capability, which reflect bactericidal activity, were not affected by administration of SPG. Two patients complained of pain at the site of inyection. Other side effects were not observed.
